|
|
|
| The effect of Linezolid combined with Ambroxol Hydrochloride on ventilator-associated pneumonia and serum PSP/sTREM-1 levels |
| GONG Gu1 HU Zhansheng2 |
1.Intensive Care Unit, Jinzhou Central Hospital, Liaoning Province, Jinzhou 121000, China;
2.Intensive Care Unit, the First Affiliated Hospital of Jinzhou Medical University, Liaoning Province, Jinzhou 121000, China |
|
|
|
Abstract Objective To analyze the effect of Linezolid combined with Ambroxol Hydrochloride on Ventilator associated pneumonia (VAP) and its effect on serum PSP/sTREM-1 levels. Methods A total of 90 patients with VAP admitted in Jinzhou Central Hospital from October 2016 to October 2017 were collected and they were divided into observation group and control group according to the random number table method, with 45 cases in each group. The control group was treated with Linezolid, while the observation group was treated with Linezolid and Ambroxol Hydrochloride. Both groups were treated for 7 days. The clinical efficacy, clinical indices, serum inflammatory factors, PSP and sTREM-1 levels were compared between the two groups. Results After treatment, the total effective rate, pathogen clearance rate, sputum suction times, mechanical ventilation time, the time of ICU hospitalization, and the serum inflammatory factor levels in the observation group were significantly better than those in the control group (P ＜ 0.05). Compared with before treatment, the serum levels of PSPN and TREM-1 in the two groups significantly decreased after treatment, and the levels of PSPN and TREM-1 in the observation group were significantly lower than those in the control group (P ＜ 0.05). Conclusion The combination of Linezolid and Ambroxol Hydrochloride has a significant effect in the treatment of VAP, that can effectively improve the antibacterial efficacy, reduce serum PSP and sTREM-1 levels, so as to improve inflammatory response and prognosis.
|
|
|
|
|
|
[1] 江梅，刘冬冬，黎毅敏.呼吸机相关性肺炎诊疗指南循证解读[J].中国循证医学杂志，2016，16（1）：33-35.
[2] 韦艳，李晓阳，丁丽丽，等.重症监护病房呼吸机相关性肺炎的危险因素分析[J].中国感染与化疗杂志，2014，14（1）：7-10.
[3] Tanr?覦verdi H，Tor MM，Kart L，et al. Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia [J]. Ann Thorac Med，2015，10（2）：137-142.
[4] 钟韵，陈奕慧.某医院临床多重耐药菌分布及细菌耐药性分析[J].中国消毒学杂志，2016，33（12）：1212-1214.
[5] 齐志丽，刘培，庄海舟，等.重症监护病房院内获得性感染的临床分析[J].首都医科大学学报，2018，39（1）：41-44.
[6] 陈庆丽.利奈唑胺对比万古霉素治疗老年呼吸机相关肺炎的临床研究[J].中国临床药理学杂志，2015，31（15）：1477-1479.
[7] 刘毅梅，王俊义，陈渊，等.氨溴索联合异丙托溴铵治疗老年患者呼吸机相关性肺炎的疗效[J].中华老年医学杂志，2015，34（8）：866-868.
[8] 梁微波，庞晓清，刘晓青，等.动态监测血清可溶性髓样细胞触发受体１对脓毒症的诊断及预后评估价值[J].中国呼吸与危重监护杂志，2014，13（1）：53-57.
[9] 曾今诚，孔彬，向文玉，等.血清可溶性髓样细胞触发受体１对活动性肺结核的早期预警和预后判断价值[J].细胞与分子免疫学杂志，2015，31（2）：235-238.
[10] 毛云，盛孝燕，朱红阳，等.血清降钙素原和可溶性髓样细胞触发受体-1及可溶性CD14亚型水平联合预测脓毒症患者28d病死率的价值研究[J].中国全科医学，2017，20（36）：4494-4500.
[11] 彭红艳，祝益民，张新萍，等.胰石蛋白对脓毒症患儿病情评估的价值[J].中国当代儿科杂志，2015，17（11）：1183-1188.
[12] 阿布都萨拉木·阿布拉，王毅，马龙，等.降钙素原清除率在呼吸机相关性肺炎疗效评价及预后判断中的应用价值[J].中华危重病急救医学，2014，26（11）：780-784.
[13] 刘卫平，孙德俊，闫志刚，等.呼吸机相关性肺炎危险因素分析[J].中华医院感染学杂志，2017，27（1）：85-87.
[14] 陈仁辉，陶福正，陈英姿，等.呼吸机相关性肺炎的危险因素与病原菌分析[J].中华医院感染学杂志，2014，24（24）：6042-6044.
[15] 李英芹，周萍.重症监护病房医院感染特点及危险因素分析[J].现代仪器与医疗，2017，23（6）：85-87.
[16] 沈威.ICU呼吸机相关肺炎病原菌及多重耐药菌的危险因素分析[J].中国现代医生，2018，56（10）：8-11.
[17] Yamaya M，Nishimura H，Nadine LK，et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells [J]. Arch Pharm Res，2014，37（4）：520-529.
[18] 张启龙，高隆，杨俊.血清胰石蛋白水平对于呼吸机相关肺炎患者临床预后的预测研究[J].华南国防医学杂志，2017，31（2）：84-88.
[19] 陈少霖，张卫星，张声，等.可溶性髓样细胞触发受体-1在呼吸机相关性肺炎的早期诊断及预后评估中的临床应用[J].中华医院感染学杂志，2017，27（13）：2968-2971.
[20] 潘定康，陈怿，段鹏凯，等.血清可溶性髓样细胞触发受体-1对重症脓毒症患者预后判断价值[J].第三军医大学学报，2016，38（8）：845-849.
[21] 吴娟，沙杭.稳定期慢性阻塞性肺疾病患者血清可溶性髓样细胞触发受体-1的检测及临床意义[J].实用医学杂志，2016，32（10）：1609-1612.
[22] 丁磊，王振洲.降钙素原联合临床肺部感染评分在呼吸机相关性肺炎早期诊断中的应用[J].临床和实验医学杂志，2018，17（4）：418-422. |
|
|
|
